There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38767553.
- Also identified by DOI 10.1158/1078-0432.CCR-24-0772.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Progression-free survival as a primary endpoint for comparative trials does not fully capture the therapeutic risk/benefit ratio. Additionally, summarization of the treatment effect via a hazard ratio is problematic when the proportional hazards assumption is violated. Restricted mean survival time metrics may address these challenges but have other limitations. See related article by Chang et al., p. 3282.
Medical subject headings
- Neoplasms
- Clinical Trials as Topic